

CLAIMS

1. The use of cystine and/or cysteine to prepare oral medicinal products for the prevention and treatment of oxidative stress resulting from
5 haemodialysis treatment in patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases or of End-Stage Renal Disease.
2. The use according to claim 1, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering
10 from chronic kidney failure.
3. Use as claimed in claim 1 or 2, wherein the cystine and/or cysteine is administered in unit doses ranging from 200 to 1000 mg.
4. Use as claimed in claim 1, 2 or 3, wherein the cystine and/or cysteine is administered before and/or after haemodialysis treatment.
- 15 5. Use as claimed in any one of claims from 1 to 4, wherein the cystine and/or cysteine is used in association with other substances such as taurine, lipoic acid, and vitamins A, C and E.
6. Pharmaceutical compositions for oral administration for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in
20 patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases, containing cysteine or cystine as active constituent.
7. A method for the prevention and treatment of oxidative stress resulting from haemodialysis in patients suffering from chronic kidney failure
25 comprising the administration to said patient from 200 to 1000 mg of cystine and/or cysteine orally before and/or after the haemodialysis treatment.
8. A method for the prevention and treatment of patients suffering from acute or chronic kidney failure comprising the oral administration to said

patient from 200 to 1000 mg of cystine and/or cysteine.

9. A method for the prevention and treatment of patients suffering from End-Stage Renal-Disease comprising the oral administration to said patient from 200 to 1000 mg of cystine and/or cysteine.